Projekt · Dnr 2017-01576 · Källa: Vinnova

E!11019, OptiFemVac, Abera Bioscience AB

Koordinator
Abera Bioscience AB
Projekttid
2017-04-01 till 2020-03-31 (avslutat)
Beviljat bidrag
2 351 980 SEK
Diarienummer
2017-01576

Beskrivning

The purpose was to engineer bacterial outer membrane vesicles (OMVs) into a versatile and modular platform for recombinant vaccine development. Technology was developped to couple high amounts of antigenic proteins to OMV particles and vaccine candidates against either Zika virus or Humano papiloma virus (HPV)-placental malaria (PM) were produced as proof-of-concept. Animal studies showed successful induction of anti-viral antibodies and inhibition of malaria binding to red blood cells. Follow-up studies will demonstrate the full potential of the OMV vaccine prototypes. In addition to vaccine prototypes against Zika and HPV-malaria infections, the project yielded a broadly applicable platform for the development recombinant OMV-based vaccines. Combined use of different versions of Tag/Catcher technology allows for the coupling of multiple different antigens from any source at a single OMV particle. This feature can be exploited to develop multivalent OMV-based vaccines, not only against viruses and parasites, but also against bacteria and even cancer.

Öppna hos Vinnova

Hittar Vinnova inte sidan? Sök på diarienumret hos Vinnova.

Liknande

  1. Improved, affordable single strain whole cell-B subunit oral cholera vaccine

    Göteborgs universitet · 2017-06-01 · 5 950 000 SEK · Projekt

    The goal has been to develop an improved, thermostable and affordable enterocoated capsule oral cholera vaccine (OCV), "Hillchol-B", based on lyophilized formalin-inactivated serotype Hikojima bacteria and recombinantly produced cholera toxin B subunit (rCTB). This has been accomplished at lab scale…

  2. Biosensor Platform for Tropical Disease Detection

    AligND AB · 2019-12-09 · 85 256 SEK · Projekt

    The goal of the project was to plan a project for the development of a next-generation biosensor platform for tropical disease detection. The goal was achieved by attending a meeting in Brazil, moreover, Vinnova´s support was helpful to initiate the joint development of the planned sensor. All partn…

  3. Nytt vaccin mot mastit hos nötkreatur orsakad av Staphylococcus aureus

    Intervacc AB · 2020-05-01 · 1 943 296 SEK · Projekt

    Mastitis is one of the most important diseases in dairy cattle causing significant losses to the dairy industry. Staphylococcus aureus is the causative agent of around 25% of contagious mastitis cases in Europe, accounting for over 2.6 million cases at an annual cost of 597M€. This project aimed to …

  4. Klinisk utvärdering av ett nytt Ultra-snabbt Antibiotikakänslighetstest för Blodinfektioner.

    Astrego Diagnostics AB · 2018-12-01 · 1 671 000 SEK · Projekt

    1) Production of Astrego’s disposable cartridges to be used for the aimed verification and implementation of design improvements: this objective has been fulfilled. 2) Verification of the Astrego® Technology for direct AST from blood culture bottles in a prospective clinical study: This objective wa…

  5. DVD/250604 - Country support for the prevention and control of HIV/AIDS, tuberculosis, viral hepatitis and sexually transmitted infections in EU/EEA and neighbouring countries

    European Centre for Disease Prevention and Control · 2025-10-23 · sista anbudsdag 2025-12-05 · 1 000 000 EUR · Upphandling

    The purpose of this framework contract is to provide a framework under which the following services can be requested: the provision of a diverse (in both methodology and size) range of scientific and technical capacity building activities, in line with the strategic priorities of countries. The focu…